- Home
- EAD vs MIRM Comparison
EAD vs MIRM Comparison
Compare EAD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- MIRM
- Stock Information
- Founded
- EAD 2003
- MIRM 2018
- Country
- EAD United States
- MIRM United States
- Employees
- EAD N/A
- MIRM N/A
- Industry
- EAD Finance/Investors Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- EAD Finance
- MIRM Health Care
- Exchange
- EAD Nasdaq
- MIRM Nasdaq
- Market Cap
- EAD N/A
- MIRM 1.9B
- IPO Year
- EAD N/A
- MIRM 2019
- Fundamental
- Price
- EAD $6.44
- MIRM $39.10
- Analyst Decision
- EAD
- MIRM Strong Buy
- Analyst Count
- EAD 0
- MIRM 11
- Target Price
- EAD N/A
- MIRM $58.55
- AVG Volume (30 Days)
- EAD 178.9K
- MIRM 476.2K
- Earning Date
- EAD 01-01-0001
- MIRM 05-07-2025
- Dividend Yield
- EAD 8.91%
- MIRM N/A
- EPS Growth
- EAD N/A
- MIRM N/A
- EPS
- EAD N/A
- MIRM N/A
- Revenue
- EAD N/A
- MIRM $336,888,000.00
- Revenue This Year
- EAD N/A
- MIRM $29.51
- Revenue Next Year
- EAD N/A
- MIRM $20.27
- P/E Ratio
- EAD N/A
- MIRM N/A
- Revenue Growth
- EAD N/A
- MIRM 80.76
- 52 Week Low
- EAD $5.69
- MIRM $23.14
- 52 Week High
- EAD $6.81
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- EAD 42.06
- MIRM 34.64
- Support Level
- EAD $6.14
- MIRM $37.83
- Resistance Level
- EAD $6.46
- MIRM $40.32
- Average True Range (ATR)
- EAD 0.18
- MIRM 2.47
- MACD
- EAD -0.00
- MIRM -0.33
- Stochastic Oscillator
- EAD 53.92
- MIRM 25.14
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.